WEBULL

Early Glioblastoma Trial Success Might Change the Case for Investing in ImmunityBio (IBRX)

Simply Wall St · 09/03/2025 11:45
  • In late August 2025, ImmunityBio announced early results from a pilot study in recurrent glioblastoma showing that all five patients treated with its investigational immunotherapy regimen achieved disease control, with three responding and two displaying stable disease.
  • This small cohort result is particularly eye-catching because glioblastoma is a challenging cancer with a very low five-year survival rate, especially among older adults.
  • We'll explore how the enthusiasm generated by 100% disease control in early trial patients could influence ImmunityBio's investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

What Is ImmunityBio's Investment Narrative?

For those considering ImmunityBio as an investment, the big picture centers on believing in the company’s ability to deliver breakthrough immunotherapy treatments and commercial success despite ongoing financial risks. The recent early-stage glioblastoma news brings renewed energy to a pipeline story that had previously been overshadowed by high cash burn, repeated equity raises, and concerns about dilution. Near-term catalysts could shift meaningfully if the glioblastoma study paves the way for larger, later-stage trials, especially since the result arrived alongside rapidly rising revenues. However, the company remains unprofitable, with growing but still modest sales and negative equity. The recent price action has not yet reflected a major move since the news, suggesting market participants may be waiting to see further clinical progress before reassessing risk. This adds a layer of uncertainty to both risk and catalyst outlooks going forward.

On the other hand, recent share dilution remains a critical consideration investors should not overlook. Upon reviewing our latest valuation report, ImmunityBio's share price might be too optimistic.

Exploring Other Perspectives

IBRX Community Fair Values as at Sep 2025
IBRX Community Fair Values as at Sep 2025
Simply Wall St Community members have shared nine different fair value views for ImmunityBio, stretching from US$0.33 to US$30. This wide spread of investor opinions sits alongside recent clinical progress but also persistent financial risks, inviting you to weigh several contrasting outlooks on the potential for future performance.

Explore 9 other fair value estimates on ImmunityBio - why the stock might be a potential multi-bagger!

Build Your Own ImmunityBio Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.